EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer
P Cornford, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
Lutetium Lu 177 vipivotide tetraxetan: first approval
SJ Keam - Molecular diagnosis & therapy, 2022 - Springer
Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as 177Lu-PSMA-617)
is a radioligand therapeutic agent that is being developed by Advanced Accelerator …
is a radioligand therapeutic agent that is being developed by Advanced Accelerator …
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman… - European journal of …, 2023 - Springer
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective …
Summary Background Lutetium-177 (177 Lu) prostate-specific membrane antigen (177 Lu-
PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate …
PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate …
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Summary Background Lutetium-177 [177 Lu] Lu-PSMA-617 is a radiolabelled small
molecule that delivers β radiation to cells expressing prostate-specific membrane antigen …
molecule that delivers β radiation to cells expressing prostate-specific membrane antigen …
Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic …
177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …
[HTML][HTML] Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients
MP Yadav, S Ballal, RK Sahoo, M Tripathi, A Seth… - Theranostics, 2020 - ncbi.nlm.nih.gov
Rationale: Despite the success of several standards of care treatment options in metastatic
castration-resistant prostate cancer (mCRPC), a significant number of patients attain …
castration-resistant prostate cancer (mCRPC), a significant number of patients attain …
Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer …
Prostate-specific membrane antigen (PSMA) may be targeted for both diagnostic and
therapeutic purposes in the management of prostate cancer (PCa). In preclinical models …
therapeutic purposes in the management of prostate cancer (PCa). In preclinical models …
TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical …
Objective To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177Lu‐PSMA‐617, a novel radiolabelled small molecule that binds with high affinity to …
with 177Lu‐PSMA‐617, a novel radiolabelled small molecule that binds with high affinity to …
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
HD Hummel, P Kufer, C Grüllich… - …, 2021 - Taylor & Francis
Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell
engager (BiTE®) immune therapy mediating T-cell killing of tumor cells in patients with …
engager (BiTE®) immune therapy mediating T-cell killing of tumor cells in patients with …